Compare Stocks: MESO, ABVX, KNSA, and IONS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$89.91 +1.3%	$98.99	$69.81 ▼ $148.83	$7.86B	1.36	1.39 million shs	462,429 shs
IONS Ionis Pharmaceuticals	$40.20 -0.5%	$48.22	$39.33 ▼ $86.74	$6.68B	0.43	2.66 million shs	1.86 million shs
KNSA Kiniksa Pharmaceuticals International	$95.82 +2.7%	$79.67	$37.02 ▼ $98.48	$7.47B	0.07	705,080 shs	581,332 shs
MESO Mesoblast	$14.32 -3.0%	$14.84	$11.89 ▼ $21.50	$1.86B	2.21	234,823 shs	243,183 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	+4.48%	+1.97%	-4.49%	-29.25%	-10.26%
IONS Ionis Pharmaceuticals	-1.99%	-8.05%	-7.17%	-25.41%	-45.12%
KNSA Kiniksa Pharmaceuticals International	+2.74%	+4.59%	+23.09%	+19.48%	+148.97%
MESO Mesoblast	+1.58%	+12.06%	+4.90%	-1.30%	-8.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$89.91 +1.3%	$98.99	$69.81 ▼ $148.83	$7.86B	1.36	1.39 million shs	462,429 shs
IONS Ionis Pharmaceuticals	$40.20 -0.5%	$48.22	$39.33 ▼ $86.74	$6.68B	0.43	2.66 million shs	1.86 million shs
KNSA Kiniksa Pharmaceuticals International	$95.82 +2.7%	$79.67	$37.02 ▼ $98.48	$7.47B	0.07	705,080 shs	581,332 shs
MESO Mesoblast	$14.32 -3.0%	$14.84	$11.89 ▼ $21.50	$1.86B	2.21	234,823 shs	243,183 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	+4.48%	+1.97%	-4.49%	-29.25%	-10.26%
IONS Ionis Pharmaceuticals	-1.99%	-8.05%	-7.17%	-25.41%	-45.12%
KNSA Kiniksa Pharmaceuticals International	+2.74%	+4.59%	+23.09%	+19.48%	+148.97%
MESO Mesoblast	+1.58%	+12.06%	+4.90%	-1.30%	-8.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	2.88	Moderate Buy	$155.00	72.40% Upside
IONS Ionis Pharmaceuticals	2.78	Moderate Buy	$89.48	122.57% Upside
KNSA Kiniksa Pharmaceuticals International	2.78	Moderate Buy	$100.57	4.96% Upside
MESO Mesoblast	2.33	Hold	$39.00	172.33% Upside

Current Analyst Ratings Breakdown

Latest MESO, ABVX, KNSA, and IONS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/30/2026	KNSA Kiniksa Pharmaceuticals International	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$107.00 ➝ $122.00
10/28/2026	KNSA Kiniksa Pharmaceuticals International	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy (B-) ➝ Hold (C-)
10/28/2026	KNSA Kiniksa Pharmaceuticals International	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$90.00 ➝ $101.00
10/28/2026	KNSA Kiniksa Pharmaceuticals International	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$99.00 ➝ $102.00
10/28/2026	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$87.00 ➝ $110.00
10/22/2026	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/22/2026	IONS Ionis Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Market Perform ➝ Outperform	$54.00 ➝ $66.00
10/21/2026	ABVX Abivax	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
10/21/2026	IONS Ionis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/21/2026	ABVX Abivax	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$118.00 ➝ $96.00
10/20/2026	IONS Ionis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$79.00

(Data available from 11/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$6.57 per share	N/A
IONS Ionis Pharmaceuticals	$944M	7.08	N/A	N/A	$3.02 per share	13.31
KNSA Kiniksa Pharmaceuticals International	$677.56M	11.03	$0.84 per share	114.39	$9.10 per share	10.53
MESO Mesoblast	$120.25M	15.50	N/A	N/A	$4.38 per share	3.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$380.27M	-$6.06	N/A	N/A	N/A	N/A	-91.69%	-71.96%	12/21/2026 (Estimated)
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/9/2026 (Estimated)
KNSA Kiniksa Pharmaceuticals International	$59.01M	$1.30	73.65	63.45	N/A	11.58%	17.27%	12.64%	N/A
MESO Mesoblast	-$57.50M	N/A	N/A	39.78	N/A	N/A	N/A	N/A	N/A

Latest MESO, ABVX, KNSA, and IONS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	IONS Ionis Pharmaceuticals	-$1.22	N/A	N/A	N/A	$181.57 million	N/A
10/27/2026	Q3 2026	KNSA Kiniksa Pharmaceuticals International	$0.3710	$0.56	+$0.1890	$0.56	$260.66 million	$285.97 million
9/21/2026	Q2 2026	ABVX Abivax	-$0.9170	-$1.71	-$0.7930	-$1.68	$0.80 million	$1.37 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	N/A	5.97	5.97
IONS Ionis Pharmaceuticals	3.07	7.89	7.73
KNSA Kiniksa Pharmaceuticals International	N/A	3.91	3.35
MESO Mesoblast	0.19	2.43	2.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
IONS Ionis Pharmaceuticals	93.86%
KNSA Kiniksa Pharmaceuticals International	53.95%
MESO Mesoblast	1.43%

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
IONS Ionis Pharmaceuticals	1.81%
KNSA Kiniksa Pharmaceuticals International	51.98%
MESO Mesoblast	18.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	80	87.55 million	N/A	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable
KNSA Kiniksa Pharmaceuticals International	366	78.02 million	37.47 million	Optionable
MESO Mesoblast	108	130.13 million	105.67 million	Optionable

MESO, ABVX, KNSA, and IONS Headlines

Recent News About These Companies

3 Australian Founder Led Stocks With Up To 55% Fair Value Upside

November 3 at 11:26 PM | finance.yahoo.com

Mesoblast stock set for board refresh as two directors depart

November 3 at 6:25 PM | ad-hoc-news.deA

Mesoblast Limited announces board retirements and committee leadership changes ahead of 2026 annual general meeting

November 3 at 7:31 AM | msn.com

3 compelling reasons to consider buying Mesoblast shares

November 2 at 4:29 PM | msn.com

Mesoblast board members to retire ahead of planned director search

November 2 at 1:30 AM | streetinsider.com

Mesoblast Board Changes - November 1, 2026

November 2 at 1:30 AM | biospace.comB

Mesoblast Board Changes

November 1 at 7:00 PM | globenewswire.com

Mesoblast Announces Board Changes Following Ryoncil Launch

November 1 at 6:31 PM | tipranks.com

3 Australian Founder Led Stocks Trading Up To 59% Below Fair Value

October 30, 2026 | finance.yahoo.com

Mesoblast stock gains attention as Ryoncil revenue rises 44 percent

October 30, 2026 | ad-hoc-news.deA

Mesoblast (NASDAQ:MESO) Stock Breaks Above 200 Day Moving Average - Here's Why

October 30, 2026 | marketbeat.com

3 Australian Healthcare Stocks With Revenue Up To 2b

October 29, 2026 | finance.yahoo.com

Healthcare Stocks Rise: GKOS Surges 33%, TDOC Gains 30%, BHC Advances 26%, MESO Jumps Over 16%

October 29, 2026 | rttnews.com

Mesoblast Stock Jumps 17% on Nasdaq as Ryoncil Sales Climb 44% and Cash Burn Collapses in Quarterly Update

October 29, 2026 | ibtimes.com.auI

Mesoblast Limited reports first quarter FY2027 activity with 44% increase in net revenues

October 29, 2026 | msn.com

Ryoncil Growth Could Change The Case For Mesoblast Stock

October 29, 2026 | finance.yahoo.com

Mesoblast (NASDAQ:MESO) Shares Gap Up - Still a Buy?

October 29, 2026 | marketbeat.com

Australian Shares Close Higher; Mesoblast Rallies After Posting Revenue Growth

October 29, 2026 | marketscreener.comM

Inside Biotech: Mesoblast surges 24% as Ryoncil sales climb and cash spend falls sharply

October 29, 2026 | finance.yahoo.com

Why are Mesoblast shares racing 15% higher today?

October 28, 2026 | fool.com.au

Mesoblast Says Net Revenue Jumps 44% in Fiscal Q1; Shares Up 17%

October 28, 2026 | marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO, ABVX, KNSA, and IONS Company Descriptions

Abivax NASDAQ:ABVX

$89.90 +1.20 (+1.35%)

As of 03:35 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Ionis Pharmaceuticals NASDAQ:IONS

$40.20 -0.22 (-0.54%)

As of 03:35 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$95.82 +2.53 (+2.71%)

As of 03:34 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Mesoblast NASDAQ:MESO

$14.32 -0.45 (-3.04%)

As of 03:35 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MESO, ABVX, KNSA, and IONS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MESO, ABVX, KNSA, and IONS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MESO, ABVX, KNSA, and IONS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO, ABVX, KNSA, and IONS Company Descriptions

Abivax NASDAQ:ABVX

Ionis Pharmaceuticals NASDAQ:IONS

Kiniksa Pharmaceuticals International NASDAQ:KNSA

Mesoblast NASDAQ:MESO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MESO, ABVX, KNSA, and IONS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MESO, ABVX, KNSA, and IONS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MESO, ABVX, KNSA, and IONS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO, ABVX, KNSA, and IONS Company Descriptions

Abivax NASDAQ:ABVX

Ionis Pharmaceuticals NASDAQ:IONS

Kiniksa Pharmaceuticals International NASDAQ:KNSA

Mesoblast NASDAQ:MESO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools